Tricalcium phosphate and glutaraldehyde crosslinked gelatin incorporating bone morphogenetic protein--a viable scaffold for bone tissue engineering.
Bone defects caused by various etiologies must be filled with suitable substances to promote bone repair. Autogenous iliac crest graft is most frequently used, but is often associated with morbidities. Several bone graft substitutes have been developed to provide osteoconductive matrices as well as to enhance osteoinductivity. A tricalcium phosphate and glutaraldehyde crosslinked gelatin (GTG) scaffold, incorporated with bone morphogenetic proteins (BMPs), was developed to provide an alternative mean of bone tissue engineering. This study investigated differences between GTG and BMP-4 immobilized GTG (GTG-BMP) scaffolds on neonatal rat calvaria osteoblast activities. The GTG scaffold possessed an average pore size of 200 microm and a porosity of 75%. HE staining revealed uniform cell distribution throughout the scaffold 24 h post cell seeding. Alkaline phosphatase (ALP) activity of the GTG samples increased initially and then stabilized at 3 weeks postseeding. ALP activity of the GTG-BMP samples was similar to that of the GTG samples in the second and third weeks, but it continued increasing and became significantly greater than that of the GTG samples by the fourth week. Gla-type osteocalcin (Gla-OC) activity of the GTG-BMP samples was initially lower, but also became significantly greater than that of the GTG samples by the fourth week. An HE stain revealed greater numbers of attached cells and a richer matrix deposits in the GTG-BMP samples. A von Kossa stain showed larger mineralizing nodules, in greater numbers, after 4 weeks of in vitro cultivation. These findings suggest that the GTG scaffold provides an excellent porous structure, conductive to greater cell attachment and osteoblast differentiation, and that utility can be significantly enhanced by the inclusion of BMPs. A GTG-BMP scaffold holds promise as a superior bioactive material for bone tissue engineering.
Yang
Shu-Hua
SH
Institute of Biomedical Engineering, College of Engineering and College of Medicine, National Taiwan University, Taipei.
Hsu
Chung-King
CK
Wang
Kuo-Cheng
KC
Hou
Sheng-Mou
SM
Lin
Feng-Huei
FH
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D019149:Bioreactors; D019485:Bone Morphogenetic Proteins / Q000378:metabolism*; D018786:Bone Substitutes; D001842:Bone and Bones / Q000378:metabolism; D002130:Calcium Phosphates / Q000494:pharmacology*; D002478:Cells, Cultured; D003432:Cross-Linking Reagents / Q000494:pharmacology; D003470:Culture Media / Q000494:pharmacology; D005780:Gelatin / Q000737:chemistry*; D005976:Glutaral / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism; D015675:Osteocalcin / Q000378:metabolism; D051381:Rats; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*
D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; D003432:Cross-Linking Reagents; D003470:Culture Media; D015675:Osteocalcin; D005780:Gelatin; D000469:Alkaline Phosphatase; C018392:tricalcium phosphate; D005976:Glutaral